Characteristics and Outcome of ET Patients Who Progressed to MDS or AML
| Patient No. . | Sex/Age (yr) at Diagnosis of ET . | Interval Between Diagnosis of ET and MDS or AML (mo) . | Treatment Received: Months . | FAB Classification of AML or MDS . | Cytogenetic Analysis at Time of AML or MDS . | Pseudo Pelger Huet Hypolobulation and Vacuoles in Neutrophils . | p53 Mutation and/or Overexpression . | Survival (mo) . |
|---|---|---|---|---|---|---|---|---|
| Patients with 17p deletion | ||||||||
| 1 | M/72 | 46 | HU:45 | M2 AML | 46,XY,−5,der(17)tinv(5;17)(p11q14;p11) | + | + | 13 |
| 2 | M/45 | 94 | HU:93 | M2 AML | 42-45,XY,del(5)(?q11?q31),del(13) (q12q31), add(17)(p11),−(0-1)19,−21, +(0-1)22,+(0-2)mar | + | + | 6 |
| 3 | F/42 | 147 | HU:6; BUS:3; PI:76 | RAEB-T | 45 XX i (17q) | + | ND | 72+ |
| 4 | F/66 | 92 | HU:81 | RAEB | 43,X,−X,−3,−7,+9,−17,−18,−22inc | + | + | 4 |
| 5 | M/30 | 108 | HU:20; PI:75 | RAEB-T | 46,XY,add(1)(p?),del(5)(q10),−12,−17, add(20)(p11)+mar1,+mar2 | + | + | 5 |
| 6 | F/65 | 95 | HU:24, PI:48 | RA | 44,XX,−5,−7,der(17)t(5;17)(p11;p11),−18,+mar | + | + | 9 |
| 7 | F/64 | 94 | 32P; HU:94 | M4 AML | 43,XX,inv(1)(p36q22),−2,−3,add(4)(p15), del(5)(q23;q34),add(6)(p22),+8, del(9)(q10),−13,der(13),t(3;13)(p11;p11),add(16)(p13),del(17)(p12p13), del(18)(p10),−19,−21,+ r | + | + | 1 |
| Patients without 17p deletion | ||||||||
| 8 | M/67 | 60 | HU:3 | M2 AML | ND | − | ND | 16 |
| 9 | M/73 | 64 | HU:59; PI:4 | RAEB-T | ND | − | ND | 4 |
| 10 | F/72 | 76 | HU:72 | M2 AML | ND | − | ND | 1 |
| 11 | M/59 | 55 | HU:17; PI:36 | RAEB-T | 47,XY,del(5)(q12q33),del(11)(q21),der(12), t(?1;12)(p33;p13),add(16)(p13),−18, +mar,+mar2 | − | − | 2 |
| 12 | M/75 | 64 | 32P | RAEB-T | 44-45,XY,add(1)(p11),−5,−6,−(0-1)10, inv(13) (q12q32),−15,−18,+mar1, +mar2,+(0-2)mar,(1-2)ace(inc) | − | − | 7 |
| 13 | M/71 | 53 | HU:48 | RAEB-T | 46,XY | − | − | 2 |
| 14 | F/48 | 109 | HU:40 | RA | 45,XX,−5,add(14)(p11),−20,+mar1 | − | ND | 7 |
| 15 | M/73 | 72 | 32P | CMML | 46,XY | − | − | 14 |
| 16 | M/67 | 128 | MEL:12; HU:84 | CMML | ND | − | ND | 36 |
| 17 | M/43 | 95 | BUS:6 | M2 AML | 47 XY +21 | − | ND | 3 |
| Patient No. . | Sex/Age (yr) at Diagnosis of ET . | Interval Between Diagnosis of ET and MDS or AML (mo) . | Treatment Received: Months . | FAB Classification of AML or MDS . | Cytogenetic Analysis at Time of AML or MDS . | Pseudo Pelger Huet Hypolobulation and Vacuoles in Neutrophils . | p53 Mutation and/or Overexpression . | Survival (mo) . |
|---|---|---|---|---|---|---|---|---|
| Patients with 17p deletion | ||||||||
| 1 | M/72 | 46 | HU:45 | M2 AML | 46,XY,−5,der(17)tinv(5;17)(p11q14;p11) | + | + | 13 |
| 2 | M/45 | 94 | HU:93 | M2 AML | 42-45,XY,del(5)(?q11?q31),del(13) (q12q31), add(17)(p11),−(0-1)19,−21, +(0-1)22,+(0-2)mar | + | + | 6 |
| 3 | F/42 | 147 | HU:6; BUS:3; PI:76 | RAEB-T | 45 XX i (17q) | + | ND | 72+ |
| 4 | F/66 | 92 | HU:81 | RAEB | 43,X,−X,−3,−7,+9,−17,−18,−22inc | + | + | 4 |
| 5 | M/30 | 108 | HU:20; PI:75 | RAEB-T | 46,XY,add(1)(p?),del(5)(q10),−12,−17, add(20)(p11)+mar1,+mar2 | + | + | 5 |
| 6 | F/65 | 95 | HU:24, PI:48 | RA | 44,XX,−5,−7,der(17)t(5;17)(p11;p11),−18,+mar | + | + | 9 |
| 7 | F/64 | 94 | 32P; HU:94 | M4 AML | 43,XX,inv(1)(p36q22),−2,−3,add(4)(p15), del(5)(q23;q34),add(6)(p22),+8, del(9)(q10),−13,der(13),t(3;13)(p11;p11),add(16)(p13),del(17)(p12p13), del(18)(p10),−19,−21,+ r | + | + | 1 |
| Patients without 17p deletion | ||||||||
| 8 | M/67 | 60 | HU:3 | M2 AML | ND | − | ND | 16 |
| 9 | M/73 | 64 | HU:59; PI:4 | RAEB-T | ND | − | ND | 4 |
| 10 | F/72 | 76 | HU:72 | M2 AML | ND | − | ND | 1 |
| 11 | M/59 | 55 | HU:17; PI:36 | RAEB-T | 47,XY,del(5)(q12q33),del(11)(q21),der(12), t(?1;12)(p33;p13),add(16)(p13),−18, +mar,+mar2 | − | − | 2 |
| 12 | M/75 | 64 | 32P | RAEB-T | 44-45,XY,add(1)(p11),−5,−6,−(0-1)10, inv(13) (q12q32),−15,−18,+mar1, +mar2,+(0-2)mar,(1-2)ace(inc) | − | − | 7 |
| 13 | M/71 | 53 | HU:48 | RAEB-T | 46,XY | − | − | 2 |
| 14 | F/48 | 109 | HU:40 | RA | 45,XX,−5,add(14)(p11),−20,+mar1 | − | ND | 7 |
| 15 | M/73 | 72 | 32P | CMML | 46,XY | − | − | 14 |
| 16 | M/67 | 128 | MEL:12; HU:84 | CMML | ND | − | ND | 36 |
| 17 | M/43 | 95 | BUS:6 | M2 AML | 47 XY +21 | − | ND | 3 |
Abbreviations: M, male; F, female; BUS, busulfan; PI, pipobroman; MEL, melphalan; ND, not determined.